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Abstract
Background: Relapse of granulomatous epulis is common after surgery because of local irritations, hormonal 
level in vivo, or incomplete resection. Currently, if recurrence occurs, then extraction of the teeth adjacent to the 
lesion is commonly performed, which may influence the aesthetics or masticatory function. Thus, a more effec-
tive and less aggressive treatment method is urgently demanded, particularly for the recurring lesion. This study 
investigated the effects of the intralesional pingyangmycin (PYM) injections for the recurrent granulomatous 
epulis and assessed the complications.
Material and Methods: A total of 16 patients with recurrent granulomatous epulis underwent intralesional PYM 
injections, between July 2010 and June 2014. The effects and complications of the treatment were retrospectively 
reviewed.
Results: The total number of injections performed was 48 (for all patients). The median number of injections per 
patient was three (range, two to four). All cases completely recovered with no recurrence and resorption of the 
alveolar bone after a follow-up of more than 12 months. The complications included slight bleeding, local swelling 
and pain following injection. All these symptoms resolved 7 to 10 days after the injection. 
Conclusions: In summary, intralesional PYM injections may be a preferred option for recurring granulomatous 
epulis.
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Introduction
Epulis is a clinically diagnostic term referring to a reac-
tive focal connective tissue proliferation in the gingiva, 
and its exact histological nature is unknown. Epulis oc-
curs at any gender and age, but is more common in fe-
male and young people (1). Although epulis has differ-
ent classifications in the literature, the most widely ac-
cepted classification in China divides epulis into three 
main types by their tissue origin, namely, granuloma-
tous epulis (epulis haemangiomatosa), fibrous (fibroid) 
epulis and giant cell (myeloid) epulis (2).
Granulomatous epulis, a smooth or lobulated exophytic 
lesion with a deep red or purplish colour (3), is also re-
ferred to as gingival pyogenic granuloma(4,5), lobular 
capillary haemangioma of the gingiva (3), and epulis 
granulomatosa (6). Local irritants, such as calculus, 
hormonal factors, certain drugs, and poor oral hygiene, 
may contribute to the development of granulomatous 
epulis (5). The management of granulomatous epulis 
depends on the clinical manifestations. Removal of the 
causative irritants, clinical observation and follow-up 
may be suggestive when the lesion is small, painless 
and free of bleeding. Although conservative excision, 
which extends down to the periosteum and reserves 
the teeth, was the usual treatment, invasive resection, 
which includes removing the adjacent teeth, should be 
performed to treat the extensive lesion with serious 
loose tooth or the recurrent lesion (3).
Therefore, more effective and less aggressive treatment 
methods should be discovered for the recurrent granu-
lomatous epulis. In this study, the intralesional pingy-
angmycin (bleomycin [BLM] A5 hydrochloride, PYM) 
injection was used to treat the 16 patients with recurrent 
granulomatous epulis. All cases completely recovered 
without recurrence, which indicated that PYM sclero-
therapy may be an additional treatment method for the 
recurrent granulomatous epulis.
Material and Methods
Between July 2010 and June 2014, 16 patients with recur-
rent granulomatous epulis were prospectively enrolled 
for the intralesional PYM solution injection treatment 
at the Department of Oral and Maxillofacial Surgery, 
Hospital of Stomatology, Wuhan University (see Table 
1 for the clinical data). This series comprised 0 males 
and 16 females, whose ages ranged from 15 years to 38 
years, with a median age of 26.5 years. Furthermore, all 
of the patients had normal menstrual cycles, had a med-
ical history that revealed no presumable cause, and had 
no history of drinking alcohol or smoking. Informed 
consent was obtained from all instances. The study was 
approved by the review board of the Ethics Committee 
of the Hospital of Stomatology, Wuhan University.
* Inclusion criteria
1. The clinical diagnosis of all cases was epulis when 
the patients first visited the department.
2. All these cases first were admitted to the department. 
Extensive resection, including removal of the periodon-
tium, periosteum, some alveolar bone, and irritants 
around the lesion, was performed. Then, adjacent gin-
gival flap was used to close the wound, regardless of 
whether it occurred for the first time or recurred after 
surgery in other hospitals. In addition, the involved 
teeth were removed if the tooth mobility index was 
greater than 2 during surgery;
Characteristics Parameter(N)
Percentage
(%)
Age
<10 years
10 to 19 years
20 to 29 years
30 to 39 years
> 39 years
0
1
12
3
0
0
6.25
75
18.75
0
Gender MaleFemale
0
16
0
100
Number of
surgery
0
1
2
3
4
0
12
2
1
1
0
75
12.5
6.25
6.25
Time of recurrence
after surgery
< 1 month
> 1 month
16
0
100
0
Number of
injection
1
2
3
4
0
2
12
2
0
12.5
75
12.5
Table 1. Clinical data of patients with the recurrent granulomatous epulis.
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3. The histopathologic examination of the all specimens 
after surgery confirmed the diagnosis of granulomatous 
epulis (Fig. 1). 
* Exclusion criteria
1. Patients with long-term pharmacotherapy (phenytoin, 
cyclosporine, or nifedipine).
2. Pregnant patients.
3. Lesions that were definitely caused by foreign mate-
rial.
* Approach and technique
After recurrence, all patients were recommended to 
receive intralesional PYM injection. All patients with 
follow-up of more than 12 months after the final treat-
ment were included in this study. 
PYM has been described previously (7). After the re-
gional anaesthesia, PYM solution (concentration, 2 
mg/mL) was injected into the pedicel until the lesions 
slightly bled. A single dose of 3 mg per session was not 
exceeded. After injection, the patients were carefully 
observed for resolution. The injections were repeated 
seven days later if necessary.
Results
Among the 16 cases, 12 cases experienced one surgery, 
4 cases underwent multiple surgeries, and 7 cases had 
tooth extraction. All of the lesions relapsed no more 
than one month after the surgery. The total number of 
injections performed was 48. The median number of in-
jections per patient was three (range, two to four). The 
median duration of follow-up was 18 months (range, 12 
months to 24 months). Overall, in this series, all of the 
patients completely recovered with no recurrence (Fig. 
2). No difference was evident in the response rate to 
PYM injection between patients who had undergone 
previous tooth extraction and those who had not.
Small haemorrhage occurred on the surface of the lesion 
after injection, which stopped bleeding for no more than 
1 h. Slight swelling and pain occurred around the lesion 
on the second day following sclerosant injection;these 
symptoms resolved in 7 to 10 days. Approximately 
three days after injection, ulceration was observed on 
the surface of all of the lesions (Fig. 3), which vanished 
along with disappearance of the entire lesion. No other 
complications were associated with the injection.
Fig. 1. The microscopic examination (40×) of the specimens shows 
the chronic inflammatory granulation tissue with increased vascu-
larity.
Fig. 2. (A) A bright red, easily haemorrhage and well-defined tumor 
at the gingiva of the right lower second premolar was relapsed after 
surgery. (B) The lesion was disappeared after four times intralesional 
injection of PYM.
Fig. 3. The ulceration was found on the surface of the lesion about 
three days after injection.
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Discussion
It’s widely accepted that epulis is not the true neoplasm 
but the hyperplastic lesion, which is the reason why 
epulis is not referred by the World Health Organiza-
tion Classification of Tumours. Therefore, the classifi-
cation and terminology of epulis are conflicting in the 
literature. In 2004, Sapp divided epulis into four main 
kinds, namely, peripheral fibroma, peripheral ossifying 
fibroma, pyogenic granuloma (including pregnancy tu-
mour) and peripheral giant cell granuloma, based on the 
histological feature. However, other literature classified 
epulis into acanthomatous epulis, giant-cell epulis, os-
sifying epulis and periodontal fibromatous epulis. In 
2008, the Dental Dictionary categorised epulis into con-
genital of newborn, epulis fissuratum, epulis-giant cell, 
and epulis granulomatosa. Furthermore, some catego-
rizsation was also based on the age group. These dif-
ferent classifications result in the confusing diagnoses 
and treatments.
Therefore, Chinese histopathologists and doctors (1) 
summarizsed the various classifications of epulis in 
the literature and renamed the terms as follows: fibrous 
(fibroid) epulis, granulomatous epulis (epulis haeman-
giomatosa), and giant cell (myeloid) epulis (2), which 
is a straightforward nomenclature to manifest the histo-
logical type and pathogenic site. This classification was 
most widely accepted and was referred in the textbook 
of Oral and Maxillofacial Surgery in China.
Granulomatous epulis, which is also referred to as gin-
gival pyogenic granuloma, is the most common disease 
among oral pyogenic granuloma (3). Although the fac-
tors that influence the development, growth rate and 
tendency of granulomatous epulis recurrence are still 
unknown, local irritations (e.g. dental plaque, calculus, 
foreign material within the gingival crevice or injury), 
pharmacotherapy (phenytoin, cyclosporine or nifed-
ipine) and hormonal status (estrogen or pregnancy) 
should be considered when making the treatment plan 
(2,3). 
With regard to the treatment, a comprehensive treatment 
is the strategy to cure granulomatous epulis, generally 
including aetiological treatment (removal of stimulus) 
and surgical procedures (excision and biopsy of the le-
sion). However, the argument about treatment focuses 
on removing the teeth involved by the lesion, some cli-
nicians considering the high rate of recurrence suggest 
that removing the lesion and the involved teeth together 
(1), others recommend to reserve teeth in consideration 
of the aesthetics or masticatory function (2). Recently, 
more treatment protocols, including laser surgery and 
cryosurgery, were used to deal with granulomatous epu-
lis to reserve the teeth and reduce recurrence (3). Each 
protocol has its advantages. However, incomplete exci-
sion (8), continuous secretion of hormone and remain-
ing irritation could also cause the recurrence (3) even 
in some cases with teeth extraction. In this series, the 
patients with recurreding granulomatous epulis were all 
female between 15 and 38-years-old; some patients even 
had the involved teeth removed. This evidence indicat-
ed that hormonal reason may play a critical role in these 
cases. Furthermore, if surgery is still the treatment of 
choice to treat, then more extensive resection should be 
performed, including the removal of more teeth and al-
veolar bone, which were not accepted by most patients. 
More important was that more extensive surgery could 
not confirm success.
A more effective and less aggressive therapy is exigently 
acquired to treat granulomatous epulis, particularly for 
recurring lesions. In the present cases, the intralesional 
PYM injection was used for the relapsed lesions. The 
exciting result indicated that PYM sclerotherapy may 
be an additional method for the granulomatous epulis.
PYM is BLM A5 made in China extracted from Strep-
tomyces Pingyangensisn with lower pulmonary toxicity 
than BLM (2,7), which was initially applied in chemo-
therapy since 1979 (9). The cytotoxicity of PYM is pri-
marily due to DNA damage, as it destroys single- and 
double-strand DNA, such as chromosomal gaps, dele-
tions and DNA fragmentations (10). Furthermore, PYM 
has also been widely used as a sclerosing agent for treat-
ing infantile haemangiomas, venous (11) and lymphatic 
(12) malformations because of its high effect and lower 
incidence of complications . Previous studies indicated 
that intralesional PYM injection of PYM causes injury 
and detachment of endothelial cells based on cytotoxic-
ity (7). In Additional, a recent study (13) indicated that 
an endothelial-mesenchymal transition (EndoMT) in 
venous malformations was induced by PYM. These ef-
fects work together to decrease the number of vascular 
lumen, thicken the lumen walls and lead to lumen nar-
rowing or occlusion.
Granulomatous epulis share similar histopathological 
and clinical features with infantile haemangiomas (2). 
This evidence indicated that the mechanisms of intral-
esional PYM injection acting in granulomatous epulis 
may be promoting apoptosis of the endothelial cells and 
inducing EndoMT of endothelial cells. With regard to 
the complications, no report on the systemic complica-
tions caused by the intralesional PYM injection has yet 
been published. As a topical medication for injection, 
complications of PYM are mostly connected with lo-
calizsed reactions at the injection site, such as ulcera-
tion, pain, local swelling and temporary paraesthesia. 
In these cases, no systemic complication occurred; the 
only complaint was local swelling and pain, which were 
relieved six days after the injection without any inter-
vention (7,12).
Beside PYM, there are also some sclerosing agents 
which are used for granulomatous epulis or oral pyo-
genic granuloma, including absolute ethanol (14), so-
Med Oral Patol Oral Cir Bucal-AHEAD OF PRINT - ARTICLE IN PRESS                                                                                                                           PYM sclerotherapy for the recurrent GE
dium tetradecyl sulfate (STS) sclerotherapy (15) and 
corticosteroid (16). Although these sclerosing agents 
have been proven to be effective, the application limita-
tions should not be ignored. Ethanol is restrictedly used 
because some patients have an allergy to alcohol and its 
injection may cause severe soft tissue oedema (17). In-
filtrations of STS into stromal tissues induce nonspecial 
necrotic changes (3). Moreover, local nerve injury was 
reported after STS sclerotherapy of venous malforma-
tions (18).
Taken together, intralesional PYM injection was safe 
and highly effective in the treatment of granulomatous 
epulis. In the present cases, the lesions were completely 
involuted by PYM with no recurrence and no tissue 
destruction, whilereas the teeth adjacent to the lesions 
were reserved. This exciting result indicates that PYM 
sclerotherapy may become a preferred treatment modal-
ity for relapsing granulomatous epulis.
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